As KDM5B was upregulated to play an oncogenic role in multiple cancers, many chemical inhibitors of KDM5B have been extensively evaluated for their potential in targeted therapy of human cancer (Zheng et al., 2019; Fu et al., 2020). Here, KDM5B is linked to cancer.